JP2021533795A5 - - Google Patents

Info

Publication number
JP2021533795A5
JP2021533795A5 JP2021509223A JP2021509223A JP2021533795A5 JP 2021533795 A5 JP2021533795 A5 JP 2021533795A5 JP 2021509223 A JP2021509223 A JP 2021509223A JP 2021509223 A JP2021509223 A JP 2021509223A JP 2021533795 A5 JP2021533795 A5 JP 2021533795A5
Authority
JP
Japan
Prior art keywords
sequence
aav
gpr108
polypeptide
cells
Prior art date
Application number
JP2021509223A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021533795A (ja
JPWO2020041498A5 (https=
JP7451497B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/047546 external-priority patent/WO2020041498A1/en
Publication of JP2021533795A publication Critical patent/JP2021533795A/ja
Publication of JP2021533795A5 publication Critical patent/JP2021533795A5/ja
Publication of JPWO2020041498A5 publication Critical patent/JPWO2020041498A5/ja
Application granted granted Critical
Publication of JP7451497B2 publication Critical patent/JP7451497B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021509223A 2018-08-21 2019-08-21 アデノ随伴ウイルスの形質導入効率を調節するための組成物および方法 Active JP7451497B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862720859P 2018-08-21 2018-08-21
US62/720,859 2018-08-21
PCT/US2019/047546 WO2020041498A1 (en) 2018-08-21 2019-08-21 Compositions and methods for modulating transduction efficiency of adeno-associated viruses

Publications (4)

Publication Number Publication Date
JP2021533795A JP2021533795A (ja) 2021-12-09
JP2021533795A5 true JP2021533795A5 (https=) 2022-07-25
JPWO2020041498A5 JPWO2020041498A5 (https=) 2022-07-25
JP7451497B2 JP7451497B2 (ja) 2024-03-18

Family

ID=69591093

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021509223A Active JP7451497B2 (ja) 2018-08-21 2019-08-21 アデノ随伴ウイルスの形質導入効率を調節するための組成物および方法

Country Status (5)

Country Link
US (1) US12195745B2 (https=)
EP (1) EP3841109A4 (https=)
JP (1) JP7451497B2 (https=)
AU (1) AU2019325332B2 (https=)
WO (1) WO2020041498A1 (https=)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL278598B2 (en) 2018-05-11 2025-11-01 Massachusetts Eye & Ear Infirmary Altering tissue tropism of adeno-associated viruses
US12570998B2 (en) 2019-09-09 2026-03-10 Massachusetts Eye & Ear Infirmary Methods and compositions for modulating the interaction between adeno-associated virus (AAV) and the AAV receptor (AAVR) for altered bio-distribution of AAV
JP7805306B2 (ja) 2020-04-09 2026-01-23 ユニバーシティ オブ シェフィールド 遺伝子療法による治療
WO2022103826A1 (en) * 2020-11-10 2022-05-19 The Children's Hospital Of Philadelphia Compositons and methods for in vivo gene transfer
GB202215198D0 (en) 2022-10-14 2022-11-30 Univ Sheffield Gene therapy treatment
WO2025114699A1 (en) 2023-11-30 2025-06-05 Cytomos Limited Cell selection
US20250276095A1 (en) 2024-03-04 2025-09-04 Kate Therapeutics, Inc. Adeno-associated virus compositions for the treatment of duchenne muscular dystrophy
CN118207258A (zh) * 2024-03-12 2024-06-18 浙江恒驭生物科技有限公司 一种检测腺相关病毒转导滴度的敏感细胞系、构建方法及其应用
WO2025226842A1 (en) 2024-04-24 2025-10-30 Kate Therapeutics, Inc. Expression control by drg-expressed mirnas
WO2025226841A1 (en) 2024-04-24 2025-10-30 Kate Therapeutics, Inc. Gene therapy approach for treating disorders associated with tnnt2
WO2026011008A1 (en) 2024-07-02 2026-01-08 Kate Therapeutics, Inc. Expression control by skeletal muscle-expressed mirnas
WO2026011009A1 (en) 2024-07-02 2026-01-08 Kate Therapeutics, Inc. Compositions and methods for muscle disorders
WO2026030242A1 (en) 2024-07-29 2026-02-05 Kate Therapeutics, Inc. Adeno-associated virus compositions for the treatment of facioscapulohumeral muscular dystrophy
WO2026030244A1 (en) 2024-07-30 2026-02-05 Kate Therapeutics, Inc. Adeno-associated virus compositions for the treatment of limb girdle muscular dystrophy 2a
WO2026050402A1 (en) 2024-08-29 2026-03-05 Kate Therapeutics, Inc. Liver de-targeted muscle tropic capsids

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6855314B1 (en) * 2000-03-22 2005-02-15 The United States Of America As Represented By The Department Of Health And Human Services AAV5 vector for transducing brain cells and lung cells
WO2003042361A2 (en) * 2001-11-09 2003-05-22 Government Of The United States Of America, Department Of Health And Human Services Production of adeno-associated virus in insect cells
WO2004027019A2 (en) * 2002-05-01 2004-04-01 University Of Florida Research Foundation, Inc. Improved raav expression systems for genetic modification of specific capsid proteins
WO2005072364A2 (en) * 2004-01-27 2005-08-11 University Of Florida A modified baculovirus expression system for production of pseudotyped raav vector
WO2006110689A2 (en) * 2005-04-07 2006-10-19 The Trustees Of The University Of Pennsylvania Method of increasing the function of an aav vector
US9567376B2 (en) * 2013-02-08 2017-02-14 The Trustees Of The University Of Pennsylvania Enhanced AAV-mediated gene transfer for retinal therapies
AU2015335923B2 (en) * 2014-10-21 2021-04-29 University Of Massachusetts Recombinant AAV variants and uses thereof
US10081659B2 (en) * 2015-04-06 2018-09-25 The United States Of America, As Represented By The Secretary, Dept. Of Health And Human Services Adeno-associated vectors for enhanced transduction and reduced immunogenicity
US10633662B2 (en) 2015-11-10 2020-04-28 The Board Of Trustees Of The Leland Stanford Junior University Methods and compositions for modulating AAV infection
EP3448874A4 (en) * 2016-04-29 2020-04-22 Voyager Therapeutics, Inc. COMPOSITIONS FOR TREATING A DISEASE
FI3445773T3 (fi) * 2016-05-13 2023-03-30 4D Molecular Therapeutics Inc Adenoassosioituneen viruksen kapsidimuunnoksia ja niiden käyttömenetelmiä
PE20190401A1 (es) 2016-07-26 2019-03-13 Biomarin Pharm Inc Novedosas proteinas de la capside del virus adenoasociado
NZ791267A (en) * 2016-08-15 2025-11-28 Genzyme Corp Methods for detecting AAV
EP3558393A4 (en) * 2016-12-22 2020-11-11 Oregon Health & Science University ADENO-ASSOCIATED VIRAL VECTORS
WO2020014395A1 (en) 2018-07-10 2020-01-16 University Of Florida Research Foundation, Incorporated Aav vp1u chimeras
TW202532428A (zh) * 2019-04-26 2025-08-16 美商愛德維仁生物科技公司 用於玻璃體內遞送之變異體aav蛋白殼

Similar Documents

Publication Publication Date Title
JP2021533795A5 (https=)
US12534717B2 (en) AAV capsid proteins for nucleic acid transfer
JP7395550B2 (ja) 新規アデノ随伴ウイルスキャプシドタンパク質
JP2022190081A5 (https=)
Kohlbrenner et al. Successful production of pseudotyped rAAV vectors using a modified baculovirus expression system
JP2020019772A5 (https=)
IL317938A (en) Recombinant viral vectors with altered tropism and their uses for the targeted introduction of genetic material into human cells
JPWO2020041498A5 (https=)
JP2020532981A5 (https=)
KR20250025387A (ko) Aav 캡시드 변이체 및 이의 용도
JP2020519284A5 (https=)
US20240269161A1 (en) Methods and compositions for tau reduction gene therapy
KR20250007619A (ko) 신규 재조합 aav vp2 융합 폴리펩티드
JP2020533973A (ja) 改変されたホスホリパーゼドメインを含むアデノ随伴ウイルス(aav)
JP2020519294A5 (https=)
JP2025004107A (ja) ガラクトース血症の処置のための遺伝子治療
JPWO2021053222A5 (https=)
JPWO2020168222A5 (https=)
JPWO2020242984A5 (https=)
JPWO2020159970A5 (https=)
US20240318198A1 (en) Gene therapy for angelman syndrome
RU2024111148A (ru) Вирусные частицы, перенацеленные на скелетные мышцы
EP4671264A1 (en) AAV PLASMIDES COMPRISING AN ACCESSORY PROTEIN CODING SEQUENCE
HK40048783A (en) New avv capsid proteins for nucleic acid transfer
AR129387A1 (es) Composiciones y métodos para el tratamiento de deficiencias auditivas no asociadas a la edad en un sujeto humano